Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study
- PMID: 8071609
Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study
Abstract
A decreased high density lipoprotein (HDL) cholesterol level (< 35 mg/dl) has been shown to be a significant independent risk factor for coronary heart disease (CHD). Moreover, increased HDL cholesterol levels (> or = 60 mg/dl) are associated with a decreased CHD risk. Levels of HDL cholesterol and apoA-I, the major protein constituent of HDL, were measured in plasma from fasting participants in the Framingham Offspring Study (1,584 men and 1,639 women, mean age 49 +/- 10 years). In this population, an HDL cholesterol value < 35 mg/dl was observed in 18.2% of men and 3.8% of women, and these subjects had mean apoA-I levels of 104 and 106 mg/dl, respectively, and triglyceride levels of 234 and 261 mg/dl, respectively. CHD was observed in 14.2% of men and 14.5% of women in this category. An HDL cholesterol level > or = 60 mg/dl was observed in 11.7% of men and 39.3% of women, and these subjects had mean apoA-I levels of 182 and 185 mg/dl, respectively, and mean triglyceride levels of 81 and 75 mg/dl, respectively. CHD was noted in 2.7% of men and 1.9% of women in this category. HDL cholesterol levels were much more strongly related to triglycerides (r = -0.54 in men and -0.47 in women) than was apoA-I (r = -0.26 in men and -0.13 in women). The relationship between plasma HDL cholesterol and triglyceride levels was not linear. In both men and women, triglycerides, body mass index (BMI), and alcohol intake contributed significantly to HDL cholesterol and apoA-I variability.
Similar articles
-
Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study.J Lipid Res. 1994 May;35(5):779-92. J Lipid Res. 1994. PMID: 8071601 Clinical Trial.
-
Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham.Arterioscler Thromb. 1993 Oct;13(10):1429-40. doi: 10.1161/01.atv.13.10.1429. Arterioscler Thromb. 1993. PMID: 8399079
-
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.J Am Heart Assoc. 2017 Aug 3;6(8):e006636. doi: 10.1161/JAHA.117.006636. J Am Heart Assoc. 2017. PMID: 28775061 Free PMC article. Clinical Trial.
-
High-density lipoprotein, low-density lipoprotein and coronary artery disease.Am J Cardiol. 1990 Sep 4;66(6):7A-10A. doi: 10.1016/0002-9149(90)90562-f. Am J Cardiol. 1990. PMID: 2203248 Review.
-
Searching for a successful HDL-based treatment strategy.Biochim Biophys Acta. 2014 Jan;1841(1):162-7. Biochim Biophys Acta. 2014. PMID: 24466591 Review.
Cited by
-
High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study.Atherosclerosis. 2007 Jun;192(2):384-90. doi: 10.1016/j.atherosclerosis.2006.05.024. Epub 2006 Jun 19. Atherosclerosis. 2007. PMID: 16787648 Free PMC article.
-
Ethanol-mediated upregulation of APOA1 gene expression in HepG2 cells is independent of de novo lipid biosynthesis.Lipids Health Dis. 2020 Jun 20;19(1):144. doi: 10.1186/s12944-020-01309-4. Lipids Health Dis. 2020. PMID: 32563265 Free PMC article.
-
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.Eur Heart J. 2010 Feb;31(4):480-8. doi: 10.1093/eurheartj/ehp601. Epub 2010 Jan 22. Eur Heart J. 2010. PMID: 20097702 Free PMC article. Clinical Trial.
-
Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.J Lipid Res. 2018 Dec;59(12):2421-2435. doi: 10.1194/jlr.M088203. Epub 2018 Oct 17. J Lipid Res. 2018. PMID: 30333156 Free PMC article.
-
Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors.Cardiovasc Res. 2016 Feb 1;109(2):294-304. doi: 10.1093/cvr/cvv241. Epub 2015 Oct 20. Cardiovasc Res. 2016. PMID: 26487692 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical